| Species |
Human |
| Protein Construction |
EphB3 (Gly34-Leu559)
Accession # P54753 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
58.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-68 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM Tris, 150mM NaCl (pH 7.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Although EphB3 expression is down-regulated in colorectal cancer (CRC) cells compared with normal intestinal epithelial cells.EphB3 is down-regulated in CRC compared to normal mucosa. Hypermethylation of CpG island is contributed to downregulation of EphB3 in CRC. EphB3 expression in tumor cells may be a useful prognostic indicator for patients with CRC. |
| Synonyms |
EK2; ETK2; HEK2; TYRO6; EPHB3; AW456895; Cek10; MDK5; Sek4; EC 2.7.10; EC 2.7.10.1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
